Literature DB >> 18752008

Identification of a hepatitis C virus mutant lacking the hypervariable region 1 in a chronically infected patient non-responding to PEG-interferon-alpha/ribavirin therapy.

D Kmieciak1, P Migdalski, J Juszczyk, P P Jagodziński, W H Trzeciak.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18752008     DOI： 10.1007/s10096-008-0608-1

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  11 in total

1.  Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees.

Authors:  X Forns; R Thimme; S Govindarajan; S U Emerson; R H Purcell; F V Chisari; J Bukh
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

2.  A 385 insertion in the hypervariable region 1 of hepatitis C virus E2 envelope protein is found in some patients with mixed cryoglobulinemia type 2.

Authors:  M Gerotto; F Dal Pero; S Loffreda; F B Bianchi; A Alberti; M Lenzi
Journal:  Blood       Date:  2001-11-01       Impact factor: 22.113

3.  Analysis of hepatitis C virus hypervariable region 1 sequence from cryoglobulinemic patients and associated controls.

Authors:  Gabriella Bianchettin; Claudia Bonaccini; Romina Oliva; Anna Tramontano; Agostino Cividini; Milvia Casato; Giampaolo Merlini; Enrico Silini; Mario U Mondelli
Journal:  J Virol       Date:  2007-02-21       Impact factor: 5.103

4.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

Review 5.  Predictors of response to therapy for chronic hepatitis C.

Authors:  Peter Ferenci
Journal:  Semin Liver Dis       Date:  2004       Impact factor: 6.115

6.  Characterization of hepatitis C virus deletion mutants circulating in chronically infected patients.

Authors:  Suwanna Noppornpanth; Saskia L Smits; Truong Xuan Lien; Yong Poovorawan; Albert D M E Osterhaus; Bart L Haagmans
Journal:  J Virol       Date:  2007-08-29       Impact factor: 5.103

7.  The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus.

Authors:  Elisa Scarselli; Helenia Ansuini; Raffaele Cerino; Rosa Maria Roccasecca; Stefano Acali; Gessica Filocamo; Cinzia Traboni; Alfredo Nicosia; Riccardo Cortese; Alessandra Vitelli
Journal:  EMBO J       Date:  2002-10-01       Impact factor: 11.598

8.  Mutations within protein kinase R-binding domain of NS5A protein of hepatitis C virus (HCV) and specificity of HCV antibodies in pretreatment sera of HCV-chronically infected patients and their effect on the result of treatment.

Authors:  Dariusz Kmieciak; Łukasz Kruszyna; Paweł Migdalski; Mariusz Łaciński; Jacek Juszczyk; Wiesław H Trzeciak
Journal:  Jpn J Infect Dis       Date:  2006-04       Impact factor: 1.362

9.  Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes.

Authors:  Birke Bartosch; Jean Dubuisson; François-Loïc Cosset
Journal:  J Exp Med       Date:  2003-03-03       Impact factor: 14.307

10.  Contribution of insertions and deletions to the variability of hepatitis C virus populations.

Authors:  Manuela Torres-Puente; José M Cuevas; Nuria Jiménez-Hernández; María A Bracho; Inmaculada García-Robles; Fernando Carnicer; Juan Del Olmo; Enrique Ortega; Andrés Moya; Fernando González-Candelas
Journal:  J Gen Virol       Date:  2007-08       Impact factor: 3.891
View more
  2 in total

1.  Application of a high-resolution melting technique for the rapid detection of partial replacement of HCV-1b by HCV-1a after PEG-IFNα/RBV therapy.

Authors:  M Holysz; K Bialas; P Migdalski; D Kmieciak; W H Trzeciak
Journal:  J Appl Genet       Date:  2014-11-08       Impact factor: 3.240

2.  Identification of mutations in the HVR1 and PKR-BD regions in HCV-infected patients resistant to PEG-IFNα/RBV therapy.

Authors:  M Holysz; K Bialas; P Migdalski; D Kmieciak; W H Trzeciak
Journal:  J Appl Genet       Date:  2015-01-15       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.